京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002020 京新药业

已收盘 03-23 15:00:00

{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":14.4,"timestamp":1774249416000,"preClose":15.12,"halted":0,"volume":14929754,"delay":0,"changeRate":-0.0476,"floatShares":724000000,"shares":861000000,"eps":0.8276,"marketStatus":"已收盘","change":-0.72,"latestTime":"03-23 15:00:00","open":14.93,"high":14.96,"low":14.33,"amount":218000000,"amplitude":0.0417,"askPrice":14.44,"askSize":2,"bidPrice":14.4,"bidSize":42,"shortable":0,"etf":0,"ttmEps":0.8276,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":15.12,"symbolType":"stock","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":16.63,"lowLimit":13.61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":2.3,"roa":"--","peRate":17.39971,"roe":"10.1%","epsLYR":0.83,"committee":-0.493976,"marketValue":12399000000,"turnoverRate":0.0206,"status":1,"floatMarketCap":10425000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2621857770","title":"股市必读：京新药业（002020）今年截至3月23日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621857770","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621857770?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:22","pubTimestamp":1774290133,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，京新药业报收于14.4元，下跌4.76%，换手率2.06%，成交量14.93万手，成交额2.18亿元。当日关注点来自交易信息汇总：京新药业股价连续4日下跌，当日主力资金净流出1125.98万元，散户资金逆势净流入1977.22万元。交易信息汇总股价提醒3月23日京新药业收盘报14.4元，跌4.76%，当日成交1492.98万元。前10个交易日主力资金累计净流入3164.45万元，同期股价累计下跌6.03%；融资余额累计减少441.32万元，融券余量累计增加5100股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400002159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2620012240","title":"京新药业：公司的盐酸卡立哌嗪胶囊审评工作持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2620012240","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620012240?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:24","pubTimestamp":1773923048,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月19日在投资者关系平台上答复投资者关心的问题。投资者提问：请问盐酸卡利拉嗪胶囊还没有获批，是因为要发补吗？京新药业回复：您好！公司的盐酸卡立哌嗪胶囊审评工作持续推进中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900035658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2620424002","title":"京新药业：集采背景下仿制药价格调整对毛利率有一定影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620424002?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:24","pubTimestamp":1773923045,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月19日在投资者关系平台上答复投资者关心的问题。投资者提问：在集采下，京新阿司匹林只卖三分多钱一片，请问阿司匹林，瑞舒伐他汀，左乙拉西坦，舍曲林在集采下毛利大概多少？京新药业回复：您好！集采背景下，仿制药价格调整对毛利率有一定影响，但是，公司希望可以借助集采带来的机会，以价换量，保持业绩稳定增长。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900035651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2620253753","title":"京新药业：公司JX11502已经完成了临床II期","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620253753?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:18","pubTimestamp":1773836288,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问11502项目三期临床何时启动？何时结束京新药业回复：您好！公司JX11502已经完成了临床II期，相关情况敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800037461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2620532212","title":"京新药业：目前盐酸卡立哌嗪胶囊审评工作在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2620532212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620532212?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:15","pubTimestamp":1773836112,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司盐酸卡立哌嗪已通过技术审评达一个多月了，难道行政审批这么慢吗？京新药业回复：您好！目前盐酸卡立哌嗪胶囊审评工作在进行中，希望可以尽快获批上市销售。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800037359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2620253220","title":"京新药业：地达西尼的对外授权工作持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620253220?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:15","pubTimestamp":1773836109,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司官网几次说地达西尼已成功完成海外授权，而公司在互动易上却每次说正在推进中。问到底什么情况？为什么公司回答不一样？京新药业回复：您好！地达西尼的对外授权工作持续推进中，但是会首先推进可以相对快速上市地区的授权工作，这样可以快速给公司贡献收入和利润。具体情况敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800037356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2618485709","title":"京新药业：公司的左乙拉西坦片已经经过几轮集采的续约","url":"https://stock-news.laohu8.com/highlight/detail?id=2618485709","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618485709?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:24","pubTimestamp":1773221060,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问左乙拉西坦有没有中选最新一期国采京新药业回复：您好，公司的左乙拉西坦片已经经过几轮集采的续约。谢谢!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100028928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2618485059","title":"京新药业：地达西尼作为公司的首个创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2618485059","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618485059?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:24","pubTimestamp":1773221060,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问地达西尼所谓授权正在进行中，是跟菲律宾医药公司在谈么？京新药业回复：您好！地达西尼作为公司的首个创新药，一方面，希望取得较好的销售业绩；另一方面，也希望可以在一些国家推进授权工作，为公司贡献利润。目前相关工作在积极推进中，敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100028927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","06978","BK0239","BK1161","002020"],"gpt_icon":0},{"id":"2618948549","title":"京新药业：盐酸卡立哌嗪胶囊审评工作在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2618948549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618948549?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:24","pubTimestamp":1773221059,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司盐酸卡利拉嗪技术审评完成了吗？京新药业回复：您好！我司申报“盐酸卡利拉嗪”经国家药典委通用名核准后名称为“盐酸卡立哌嗪”。目前盐酸卡立哌嗪胶囊审评工作在进行中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100028925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2618794861","title":"京新药业：目前公司的领雁项目整体正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2618794861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618794861?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:24","pubTimestamp":1773221049,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司领雁项目进展如何？京新药业回复：您好！目前公司的领雁项目整体正常推进中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100028914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2618485419","title":"京新药业：公司JX11502已经完成了临床II期","url":"https://stock-news.laohu8.com/highlight/detail?id=2618485419","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618485419?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:24","pubTimestamp":1773221048,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问Jx11502管线具体进展如何，为何在港股招股书中未提及？是否失败了？京新药业回复：您好！公司JX11502已经完成了临床II期。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100028913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2618955976","title":"股市必读：京新药业（002020）3月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2618955976","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618955976?lang=zh_cn&edition=full","pubTime":"2026-03-09 01:42","pubTimestamp":1772991736,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，京新药业报收于15.73元，上涨2.48%，换手率1.38%，成交量9.96万手，成交额1.56亿元。董秘最新回复投资者： 问公司吕董公司新申报的jX2414注射液主要用于治疗什么？公司的降脂新药LPJX2201对外授权工作正在推进中。盐酸卡利拉嗪胶囊正在推进其审评工作，暂未收到批准上市的批文。当日关注点来自交易信息汇总：3月6日主力与游资资金均呈净流出状态，散户资金净流入超千万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900000757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2617450088","title":"京新药业：公司的降脂新药LP（a）JX2201对外授权工作正在推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2617450088","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617450088?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:18","pubTimestamp":1772781502,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月06日在投资者关系平台上答复投资者关心的问题。投资者提问：公司降脂新药BD业务到底推进到什么程度了，？另外盐酸卡利拉嗪这个大单品应该获批了吧！公司如何推介，毫不客气的说全球除国内销售额已达300亿，国内将来怎么也达到30~40亿吧？京新药业回复：您好！公司的降脂新药LP（a）JX2201对外授权工作正在推进中。盐酸卡利拉嗪胶囊正在推进其审评工作，暂未收到批准上市的批文。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600018842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2617500854","title":"京新药业：公司地达西尼的授权工作在积极推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2617500854","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617500854?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:15","pubTimestamp":1772781321,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月06日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司多次宣传地达面尼浣成国外授权。问具体情况是什么？正面回答！京新药业回复：您好！公司地达西尼的授权工作在积极推进，敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600018823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2617507093","title":"京新药业：公司的JX2414注射液主要用于治疗精分激越","url":"https://stock-news.laohu8.com/highlight/detail?id=2617507093","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617507093?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:12","pubTimestamp":1772781139,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)03月06日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董公司新申报的jX2414注射液主要用于治疗什么？为什么创新药都开始申报了，投资者都不知道？京新药业回复：您好!公司的JX2414注射液主要用于治疗精分激越。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600018799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2616378734","title":"股市必读：京新药业（002020）3月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2616378734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616378734?lang=zh_cn&edition=full","pubTime":"2026-03-04 02:06","pubTimestamp":1772561178,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，京新药业报收于15.57元，下跌2.01%，换手率1.55%，成交量11.21万手，成交额1.77亿元。董秘最新回复投资者： 问吕董，别的公司都大力推介公司，反观公司手握几个大单品创新药及全球垄断性原料药。公司二级市场上反而比不过化工类公司。另公司近半年多时间老是遮遮掩掩，利好信息从不主动公告。当日关注点来自交易信息汇总：3月3日主力资金净流出2327.68万元，显示主力资金逢高减持迹象。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400001173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2616876100","title":"股市必读：京新药业（002020）2月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2616876100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616876100?lang=zh_cn&edition=full","pubTime":"2026-03-02 03:11","pubTimestamp":1772392269,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，京新药业报收于16.34元，上涨0.62%，换手率0.98%，成交量7.13万手，成交额1.17亿元。董秘最新回复投资者： 问公司吕董，公司地达西尼26年前两月环比去年四季度销售额增长了吗？公司在努力推进地达西尼的销售工作，目前销售情况良好。公司的降脂新药LPJX2201的临床I期已完成入组，正在完善临床报告。当日关注点来自交易信息汇总：2月27日主力资金净流出314.61万元，游资资金净流出465.8万元，散户资金净流入780.41万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2614981363","title":"京新药业：降脂新药LP（a）JX2201的临床I期已完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2614981363","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614981363?lang=zh_cn&edition=full","pubTime":"2026-02-28 16:21","pubTimestamp":1772266869,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)02月28日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司降脂新药，一期临床结束了吗？效果如何？BD推进到什么程度了。怏一年了！！！京新药业回复：您好！公司的降脂新药LP（a）JX2201的临床I期已完成入组，正在完善临床报告。对外授权工作也在推进中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022800009442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2614813932","title":"京新药业：公司在努力推进地达西尼的销售工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2614813932","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614813932?lang=zh_cn&edition=full","pubTime":"2026-02-28 16:21","pubTimestamp":1772266866,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)02月28日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司地达西尼26年前两月环比去年四季度销售额增长了吗？京新药业回复：您好!公司在努力推进地达西尼的销售工作，目前销售情况良好。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022800009439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2614018259","title":"京新药业：盐酸卡利拉嗪胶囊正在推进其审评工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2614018259","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614018259?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:21","pubTimestamp":1772094092,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：盐酸卡利拉嗪胶囊评审公示已经撤除，是不是评审阶段已经结束，等待批文？京新药业回复：您好！盐酸卡利拉嗪胶囊正在推进其审评工作，暂未收到批准上市的批文。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600023557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774310513467,"stockEarnings":[{"period":"1week","weight":-0.1193},{"period":"1month","weight":-0.1331},{"period":"3month","weight":-0.2899},{"period":"6month","weight":-0.3343},{"period":"1year","weight":0.0869},{"period":"ytd","weight":-0.2413}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22318人(较上一季度减少86.05%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":"　　浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}